Athenex

98 articles with Athenex

• Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020

  10/22/2020

  Athenex, Inc. announced that it will release third quarter 2020 financial results on Thursday, November 5, 2020, before the market opens, and host a conference call and live audio webcast 8:00am Eastern Time to discuss financial results and provide a business update.

• Athenex Oncology launches Your Guide to Facing Metastatic Breast Cancer, a first-of-its-kind self-care resource for people living with metastatic breast cancer (MBC)

  10/9/2020

  Athenex, Inc. (NASDAQ: ATNX), today announced that Athenex Oncology, a U.S. based division of Athenex, launched Your Guide to Facing Metastatic Breast Cancer -- a free, first-of-its-kind resource offering comprehensive lifestyle guidance to people living with metastatic breast cancer (MBC)

• Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell TherapyAthenex’s first T cell therapy product cleared to advance to the first stage of clinical development in the U.S.

  9/23/2020

  Athenex, Inc. announced that the U.S. Food and Drug Administration has allowed its Investigational New Drug application for TCRT-ESO-A2, an autologous T cell receptor -T cell therapy targeting solid tumors that are NY-ESO-1 positive in HLA-A*02:01 positive patients.

• Athenex, Inc. Announces Pricing of $110 Million Public Offering of Common Stock

  9/10/2020

  Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the pricing of a public offering of 10,000,000 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds to Athenex from the offering, before underwriting discounts and commissions and estimated offering expenses, are exp

• Quantum Leap Healthcare Collaborative and Athenex Announce the Selection of Oral Paclitaxel plus Encequidar in Combination with dostarlimab, an anti-PD-1, in the I-SPY 2 TRIAL targeting Stage 2/3 HER2+ and HER2- Breast Cancers

  9/8/2020

  Athenex’s oral paclitaxel plus encequidar is being evaluated in combination with GSK’s dostarlimab in the neoadjuvant chemotherapy setting

• Athenex, Inc. Announces Proposed Public Offering of Common Stock

  9/8/2020

  Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that it intends to offer and sell, subject to market conditions, 10,000,000 shares of its common stock in an underwritten public offering

• Athenex Announces FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review

  9/1/2020

  FDA grants Priority Review and sets PDUFA target action date of February 28, 2021 FDA indicated that it is not currently planning to hold an advisory committee meeting BUFFALO, N.Y., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has accepte

• Athenex, Inc. Reports Second Quarter Ended June 30, 2020 Financial Results and Provides Corporate Update

  8/6/2020

  Regulatory progress for Oral Paclitaxel and tirbanibulin ointment is on track Continued momentum in building commercialization infrastructure and supply chain for Oral Paclitaxel Announced two financing agreements for up to $275 million in aggregate Product sales guidance for 2020 raised to mid-teens percentage growth y/y Conference call and live webcast at 8.00am ET today

• Athenex Announces $50 Million Revenue Interest Financing with Sagard Healthcare Royalty Partners

  8/6/2020

  Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has entered into a $50 million Revenue Interest Financing (“RIF”) agreement with Sagard Healthcare Royalty Partners, LP (“SHRP”), a division of multi-strategy alternative asset manager Sagard Holdings (the “Agreement”). The Com

• Biopharmaceutical Leader Robert J. Spiegel, MD, FACP Appointed to the Athenex Board of DirectorsPharmaceutical industry veteran with significant oncology clinical development expertise appointed to Board

  8/4/2020

  Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Robert J. Spiegel, MD, FACP, a renowned biotech and pharmaceutical executive, to its Board of Directors. “We are thrilled to add an industry executive with Dr. Spiegel’s deep drug development expertise to our Board

• Athenex, Inc. to Report Second Quarter 2020 Earnings Results on August 6, 2020

  7/27/2020

  Athenex, Inc. announced that it will release second quarter 2020 financial results on Thursday, August 6, 2020, before the market opens, and host a conference call and live audio webcast 8:00am Eastern Time to discuss the financial results and provide a business update.

• Athenex Appoints Teresa Bair, Esq. as Executive Officer and General Counsel

  6/23/2020

  Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced the promotion of Teresa Bair, Esq. to Executive Officer as General Counsel and Senior Vice President, Administration.

• Athenex Announces $225 Million Loan Agreement with Oaktree

  6/22/2020

  Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it has entered into a $225 million loan agreement with funds managed by Oaktree Capital Management, L.P., a leading global investment firm.

• Athenex Oncology launches Facing MBC Together campaign to address isolation for people living with metastatic breast cancer

  6/13/2020

  Campaign features stories of hope, tears, and encouragement from a diverse group of 9 individuals with metastatic breast cancer [MBC] New website and mobile app provide vital information and resources to help people facing MBC create a personal support network and feel less isolated   [13-June-2020]   BUFFALO, N.Y. and CHICAGO , June 13, 2020 /PRNewswire/ -- A

• 

  Clinical Catch-Up: May 25-29

  6/1/2020

  In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.

• Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific Program

  5/29/2020

  Data are featured as an ASCO poster presentation and will be part of the Sarcoma Highlights Session on Sunday, May 31, 2020 at 3:30pm ET

• Athenex Announces Participation in the 2020 RBC Capital Markets Global Healthcare Virtual Conference

  5/19/2020

  Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20, 2020, at 11:30 a.m. ET. A live audio webcast of the presentation can be accessed through th

• Athenex, Inc. Reports First Quarter Ended March 31, 2020 Financial Results and Provides Corporate Update

  5/7/2020

  Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced its financial results and business highlights for the first quarter ended March 31, 2020.

• Athenex Announces Acceptance of Oral Paclitaxel Phase II Study in Angiosarcoma Abstract at ASCO20 Virtual Scientific Program

  4/29/2020

  Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract for its ongoing Phase II study of oral paclitaxel and encequidar (Oral Paclitaxel; formerly known as Oraxol),

• Athenex, Inc. to Report First Quarter 2020 Earnings Results on May 7, 2020

  4/23/2020

  Athenex, Inc. announced that it will release first quarter 2020 financial results on Thursday, May 7, 2020, before the market opens, and host a conference call and live audio webcast 8:00am Eastern Time to discuss the financial results and provide a business update.